<?xml version="1.0" encoding="UTF-8"?>
<p>In addition to the abovementioned studies, a trivalent vaccine succeeded in Phase I/II trials. An intranasal vaccine formulation was used for a delNS1-trivalent vaccine comprising the strains H1N1, H3N2 from influenza A viruses and a type-B influenza strain. Similarly to other clinical trials, this vaccine was also safe and well tolerated and IgA levels were also increased as expected [
 <xref rid="B126-ijms-21-01511" ref-type="bibr">126</xref>].
</p>
